SCHEMBL6444900

SCHEMBL6444900

CSc1nc(N)nc(-c2ccc(Cl)cc2)c1C#N

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.64
MAPT P10636 3/20 0.64
LMNA P02545 3/20 0.64
KMT2A Q03164 3/20 0.64
MEN1 O00255 2/20 0.64
MAPK1 P28482 2/20 0.64
HTT P42858 2/20 0.64
KDM4E B2RXH2 2/20 0.64
ALOX15 P16050 1/20 0.64
HSD17B10 Q99714 1/20 0.64
RXFP1 Q9HBX9 1/20 0.58
CYP1A2 P05177 3/20 0.56
CYP2C9 P11712 3/20 0.56
CYP2C19 P33261 3/20 0.56
CYP3A4 P08684 1/20 0.56
ALDH1A1 P00352 3/20 0.54
PKM P14618 2/20 0.54
GAA P10253 1/20 0.54
POLB P06746 1/20 0.53
CYP2D6 P10635 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27573259 0.87 ADORA1 (0.67) NPSR1MAPTLMNAKMT2AMEN1
SCHEMBL6440513 0.86 ADORA1 (0.65) NPSR1MAPTLMNAKMT2AMEN1
SCHEMBL6442594 0.85 ADORA1 (0.71) MAPTRXFP1CYP1A2CYP2C9CYP2C19
SCHEMBL6441875 0.83 ADORA1 (0.76) NPSR1MAPTKDM4ERXFP1CYP1A2
SCHEMBL14413001 0.80 ADORA1 (0.58) NPSR1LMNAKMT2AKDM4ERXFP1
SCHEMBL6443222 0.78 MAPT (0.66) NPSR1MAPTLMNAKMT2AMEN1
SCHEMBL6440563 0.77 CYP1A2 (0.53) NPSR1MAPTLMNAKMT2AMEN1
SCHEMBL6440532 0.77 RXFP1 (0.72) NPSR1MAPTLMNAKMT2AMEN1
SCHEMBL6441246 0.77 ADORA1 (0.69) MAPTKMT2AMAPK1HTTKDM4E
SCHEMBL6440876 0.76 MAPT (0.70) MAPTLMNAKMT2AMEN1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 NPSR1 50/4885MAPT 1878/4885LMNA 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.